Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors
- PMID: 35180829
- PMCID: PMC9271331
- DOI: 10.1089/thy.2022.0095
Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors
Conflict of interest statement
No competing financial interests exist.
Comment on
-
Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.Thyroid. 2022 May;32(5):544-551. doi: 10.1089/thy.2021.0418. Epub 2022 Jan 11. Thyroid. 2022. PMID: 34894720
References
-
- Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, Sobel VR, Schulman A, Scognamiglio T, Chritos PJ, Hassett E, Luick J, Whitehall D, Zarnegar R, Fahey TJ. 2018. Less is more: the impact of Multidisciplinary Thyroid Conference on the treatment of well-differentiated thyroid carcinoma. World J Surg 42:343–349. - PubMed
-
- Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP. 2013. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683–694. - PubMed
-
- Singer MC, Marchal F, Angelos P, Bernet V, Boucai L, Buchholzer S, Burkey B, Eisele D, Erkul E, Faure F, Freitag SK, Gillespie MB, Harrell RM, Hartl D, Haymart M, Leffert J, Mandel S, Miller, BS, Morris J, Pearce EN, Rahmati R, Ryan WR, Schaitkin B, Schlumberger M, Stack BC, Van Nostrand D, Wong KK, Randolph G. 2020. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head Neck 42:3446–3459. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical